Evaluate the renal system damage caused by zoledronic acid: a comprehensive analysis of adverse events from FAERS - Wang, Zhaojun; Su, Xin; Shi, Donglei; Wei, Li (BMC cancer, 2024)
Keywords: Adolescent; Adult; Adverse and side effects; Adverse Drug Reaction Reporting Systems; Adverse events; Aged; Aged, 80 and over; Algorithms; Bayes Theorem; Bayesian analysis; Biomedical and Life Sciences; Biomedicine; Bone Density Conservation Agents - adverse effects; Bone Density Conservation Agents - therapeutic use; Breast cancer; Cancer Research; Cancer therapies; Child; Complications and side effects; Connective tissue; Diabetes insipidus; Drug dosages; Drug-Related Side Effects and Adverse Reactions - etiology; Drugs; FDA adverse event reporting system; FDA approval; Female; Health Promotion and Disease Prevention; Humans; Hypercalcemia; Kidney diseases; Kidney Diseases - chemically induced; Lung cancer; Male; Malignancy; Medicine/Public Health; Metastases; Middle Aged; Multiple myeloma; Necrosis; Neural networks; Oncology; Osteolysis; Osteoporosis; Osteoporosis - chemically induced; Pharmacovigilance; Polyuria; Product safety; Prostate cancer; Proteinuria; Risk factors; Surgical Oncology; Surveillance; Tumors; United States - epidemiology; Young Adult; Zoledronic acid; Zoledronic Acid - adverse effects; Zoledronic Acid - therapeutic use; United States; Adverse events; Zoledronic acid; FDA adverse event reporting system